Sutro Biopharma (NASDAQ:STRO) Price Target Raised to $57.00

Sutro Biopharma (NASDAQ:STRO – Free Report) had its target price raised by Barclays from $56.00 to $57.00 in a research note released on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Several other brokerages have also commented on STRO. Wedbush restated an “outperform” rating and set a $60.00 price target on shares of Sutro Biopharma in a research note on Thursday, October 15th. Wall Street Zen downgraded Sutro Biopharma from a “sell” rating to a “strong sell” rating in a report on Sunday, November 8th. Stifel Nicolaus set a $48.00 price objective on shares of Sutro Biopharma and gave the stock a “buy” rating in a research note on Friday, August 7th. Wells Fargo & Company started coverage on shares of Sutro Biopharma in a research note on Wednesday, September 30th. They issued an “overweight” rating and a $49.00 price objective for the company. Finally, Weiss Ratings upgraded shares of Sutro Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $49.60.

Check Out Our Latest Analysis on Sutro Biopharma

Sutro Biopharma Price Performance

STRO opened at $9.82 on Friday. The stock’s fifty day moving average is $13.18 and its two-hundred day moving average is $22.54. The company has a market capitalization of $162.82 million, a P/E ratio of -0.82 and a beta of 1.56. Sutro Biopharma has a 52 week low of $7.15 and a 52 week high of $43.85.

Sutro Biopharma (NASDAQ:STRO – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($1.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.26). The business had revenue of $9.10 million during the quarter, compared to analyst estimates of $14.11 million. Equities analysts anticipate that Sutro Biopharma will post -8.12 earnings per share for the current year.

Institutional Trading of Sutro Biopharma

A number of hedge funds have recently bought and sold shares of the stock. Orbimed Advisors LLC purchased a new position in Sutro Biopharma in the first quarter valued at about $19,956,000. Perceptive Advisors LLC purchased a new stake in shares of Sutro Biopharma during the first quarter valued at about $17,818,000. ADAR1 Capital Management LLC lifted its position in shares of Sutro Biopharma by 681.8% during the first quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company’s stock valued at $13,064,000 after buying an additional 457,364 shares during the last quarter. Affinity Asset Advisors LLC lifted its position in shares of Sutro Biopharma by 42.9% during the first quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company’s stock valued at $26,642,000 after buying an additional 321,137 shares during the last quarter. Finally, Merck & Co. Inc. bought a new stake in shares of Sutro Biopharma in the 2nd quarter valued at about $9,042,053. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

(Get Free Report)

Sutro Biopharma is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro’s clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1.

See Also

Analyst Recommendations for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.